ADVANCED BREAST CANCER
Trial No. Principal Investigator Trial Name
TRIO-US Lilly 13Y-MC-JPBZ Babu A phase 2, randomized, multicenter, 3-Arm, open-label study to compare the efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to standard-of-care chemotherapy of physician's choice plus Trastuzumab in women with HR+, HER2+ locally advanced or metastatic breast Cancer
TRIO-US Novartis LEE011XUS29 Triniti -1 Babu A phase I/II, single arm, open-label study of Ribociclib in combination with Everolimus + Exemestane in treatment of men and postmenopausal women with HR+, HER2- locally advanced or metastatic breast cancer following progression on DCK 4/6 inhibitor
Novartis CBYL719C2301 SOLAR-1 Aggarwal SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment.
Triple Negative
Trial No. Principal Investigator Trial Name
TRIO-US Syndax SNDX-275-0602 (TRIO-025) Babu A randomized , placebo-controlled, double-blind, multicenter phase 2 study of Atezolizumab with or without Entinostat in patients with advanced triple negative breast cancer, with a phase 1b lead in phase {SNDX-275-0602}